Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Zoé L. E. van Kempen; Theo Rispens; Joep Killestein

doi:https://doi.org/10.1177/1352458517734073

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Zoé L. E. van Kempen, Theo Rispens, Joep Killestein

Research output: Contribution to journal › Comment/Letter to the editor › Academic

2 Citations (Scopus)

Original language	English
Pages (from-to)	822-823
Journal	MULTIPLE SCLEROSIS JOURNAL
Volume	24
Issue number	6
Early online date	9 Oct 2017
DOIs	https://doi.org/10.1177/1352458517734073
Publication status	Published - 2018

Access to Document

https://doi.org/10.1177/1352458517734073

Cite this

@article{1bf9bac4a5574359a3108a763ff9b1b8,

title = "Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”",

author = "{van Kempen}, {Zo{\'e} L. E.} and Theo Rispens and Joep Killestein",

year = "2018",

doi = "https://doi.org/10.1177/1352458517734073",

language = "English",

volume = "24",

pages = "822--823",

journal = "MULTIPLE SCLEROSIS JOURNAL",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "6",

}

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”. / van Kempen, Zoé L. E.; Rispens, Theo ; Killestein, Joep.
In: MULTIPLE SCLEROSIS JOURNAL, Vol. 24, No. 6, 2018, p. 822-823.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

AU - van Kempen, Zoé L. E.

AU - Rispens, Theo

AU - Killestein, Joep

PY - 2018

Y1 - 2018

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85043329197&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/28990853

U2 - https://doi.org/10.1177/1352458517734073

DO - https://doi.org/10.1177/1352458517734073

M3 - Comment/Letter to the editor

C2 - 28990853

SN - 1352-4585

VL - 24

SP - 822

EP - 823

JO - MULTIPLE SCLEROSIS JOURNAL

JF - MULTIPLE SCLEROSIS JOURNAL

IS - 6

ER -

Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Access to Document

Other files and links

Cite this